| Dr Paul Pyo, MD | |
|
455 Lewis Ave, Suite 210, Meriden, CT 06451-2121 | |
| (203) 238-1241 | |
| (203) 686-0791 |
| Full Name | Dr Paul Pyo |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 21 Years |
| Location | 455 Lewis Ave, Meriden, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598919045 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 25MA08498200 (New Jersey) | Secondary |
| 208800000X | Urology | 054227 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Midstate Medical Center | Meriden, CT | Hospital |
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.
With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.
Researchers have found evidence that the detached response to social cues seen in infants with autism spectrum disorder (ASD) affects development of particular brain regions known as the "social brain".
MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").
› Verified 9 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.
With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.
Researchers have found evidence that the detached response to social cues seen in infants with autism spectrum disorder (ASD) affects development of particular brain regions known as the "social brain".
MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").
› Verified 9 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.
With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.
Researchers have found evidence that the detached response to social cues seen in infants with autism spectrum disorder (ASD) affects development of particular brain regions known as the "social brain".
MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Pyo, MD 455 Lewis Ave, Suite 210, Meriden, CT 06451-2121 Ph: (203) 238-1241 | Dr Paul Pyo, MD 455 Lewis Ave, Suite 210, Meriden, CT 06451-2121 Ph: (203) 238-1241 |
News Archive
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
New research has identified that a key protein called PEA-15 stops T-cell proliferation by blocking the cell's ability to reproduce. The control of T-cell proliferation is essential in preventing certain blood cancers and autoimmune diseases, as well as the orchestration of the immune response to infection. Findings of the study are reported in a recent online issue of The FASEB Journal, a publication of The Federation of American Societies for Experimental Biology.
With peer-reviewed articles on fatigue having increased 90% over the past decade - and nearly 1,000 papers on the topic published in 2011 alone - the time is right for Routledge's new journal, Fatigue: Biomedicine, Health & Behavior.
Researchers have found evidence that the detached response to social cues seen in infants with autism spectrum disorder (ASD) affects development of particular brain regions known as the "social brain".
MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").
› Verified 9 days ago
Robert F Morrison, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 455 Lewis Ave, Ste 210, Meriden, CT 06451 Phone: 203-238-1241 Fax: 203-686-0791 | |
Kathryn Emily Wagner, Urology Medicare: Medicare Enrolled Practice Location: 455 Lewis Ave Ste 205, Meriden, CT 06451 Phone: 203-238-1241 Fax: 203-686-0791 | |
Kenneth R Kurz, Urology Medicare: Not Enrolled in Medicare Practice Location: 455 Lewis Ave, Ste 210, Meriden, CT 06451 Phone: 203-238-1241 Fax: 203-686-0791 | |
Jean F. Wong, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 455 Lewis Ave, Suite 210, Meriden, CT 06451 Phone: 203-238-1241 Fax: 203-686-0791 |